Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Cancer Stage II Clear all
Not listed Phase 2 Interventional

Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer

NCT00006433
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxil, heat treatment
Drug · Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 90 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 6:56 PM EDT
Completed No phase listed Observational

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

NCT00002900
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
management of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
105
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Jul 21, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

NCT01339000
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Bladder Cancer
Interventions
Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine, Pneumococcal Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

NCT04674306
View directory record Official record
Conditions
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
Interventions
α-lactalbumin vaccine, Zymosan
Biological
Lead sponsor
George T. Budd
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

NCT02734004
View directory record Official record
Conditions
Ovarian, Breast, SCLC, Gastric Cancers
Interventions
Olaparib, MEDI4736, Bevacizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Newnan, Georgia • Towson, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

NCT06042569
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Interventions
Cyclophosphamide, Docetaxel, Medical Chart Review, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional

Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

NCT00028483
View directory record Official record
Conditions
Breast Cancer
Interventions
cBR96-doxorubicin immunoconjugate, docetaxel
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

NCT00320541
View directory record Official record
Conditions
Breast Cancer
Interventions
gemcitabine, paclitaxel, bevacizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
30
States / cities
Fayetteville, Arkansas • La Jolla, California • Mission Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

NCT00194779
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, paclitaxel, filgrastim, capecitabine, methotrexate, vinorelbine tartrate, needle biopsy, therapeutic conventional surgery, immunohistochemistry staining method, trastuzumab, tamoxifen citrate, letrozole, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions
Palbociclib, Olaparib, Fulvestrant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

NCT00524459
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, pegylated liposomal doxorubicin hydrochloride, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 64 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer

NCT00577122
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer

NCT00001239
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
FLAC with GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

NCT06954831
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
Interventions
Cone-Beam Computed Tomography, Hypofractionated External Beam Radiation Therapy, Questionnaire Administration, Radiation Boost, Whole Breast Irradiation
Procedure · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Arcadia, California • Duarte, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Early Phase 1 Interventional Results available

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

NCT01434342
View directory record Official record
Conditions
Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
Interventions
Nicotine Replacement Patch
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting Not applicable Interventional

Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial

NCT05930483
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
¡Vida! program, ¡Vida! Plus [¡Vida! + Experiential Learning (EL)], Health Coaching, Mailed Toolkits
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

NCT01004172
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer, Progressive Breast Cancer
Interventions
carboplatin, bevacizumab, herceptin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

NCT00201773
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Celecoxib, Correlative studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Jul 21, 2026, 6:56 PM EDT
Completed No phase listed Observational

Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer

NCT02370277
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

NCT04886531
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Interventions
Neratinib, Letrozole (L) or Anastrozole (A), Trastuzumab
Drug
Lead sponsor
Ruth O'Regan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Rochester, New York • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

NCT06113016
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Exercise Intervention, Fisetin, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Alhambra, California • Beverly Hills, California • Burbank, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

NCT02278965
View directory record Official record
Conditions
Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma
Interventions
Metformin, Omega-3 fatty acids
Drug
Lead sponsor
Katherine D. Crew
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jul 21, 2026, 6:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

NCT04152499
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
Interventions
SKB264
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 21, 2026, 6:56 PM EDT
Recruiting Phase 2 Interventional

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT01174121
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
Interventions
Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 6:56 PM EDT